Regencell Bioscience Holdings Ltd
For the period ended Jun 30, 2025. Filed Jun 30, 2025.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Jun 30, 2025 · Filed Jun 30, 2025
Use the contents to explore the available documents and sections.
Contents
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Pursuant to Nasdaq Rule 5250(c)(2), Regencell Bioscience Holdings Limited (the “Company”) hereby furnishes its unaudited condensed consolidated interim balance sheets and statement of operations and comprehensive loss for its six months ended on December 31, 2024, which are attached as Exhibit 99.1 to this Form 6-K.
| Exhibit No. | Description of Exhibit |
| 99.1 | Regencell Bioscience Holdings Limited Announces First Half 2025 Management Financial Results |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.